The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.
 
Leo I. Gordon
Stock and Other Ownership Interests - Zylem
Consulting or Advisory Role - Epizyme; Gilead Sciences; Janssen Oncology; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Zylem
 
Daanish Hoda
No Relationships to Disclose
 
Ling Shi
Employment - Evidera/PPD
Stock and Other Ownership Interests - PPD Global
 
Shien Guo
Employment - Evidera
Leadership - Evidera
Stock and Other Ownership Interests - PPD; Thermo Fisher Scientific
Consulting or Advisory Role - Evidera (Inst)
 
Fei Fei Liu
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation
 
Julia Braverman
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ronald L. Dubowy
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Cellectis; Compugen; Gilead Sciences; Synairgen
Patents, Royalties, Other Intellectual Property - Bristol Myers Squibb (BMS) (Inst)
 
Lily Peng
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Alison Sehgal
Speakers' Bureau - OncLive; Peerview
Research Funding - Juno Therapeutics; Kite/Gilead; Miltenyi Biotec